PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY
Barts and The London School of Medicine and Dentistry, London, UK OBJECTIVE: Natalizumab is a new disease modifying therapy currently licensed for use in patients with relapsing-remitting multiple sclerosis (RRMS), and has recently been the subject of a cost-effectiveness evaluation by the National Institute for Health and Clinical Excellence (NICE) in the UK. NICE accepted that natalizumab was cost-effective in a highly-active subgroup of RRMS patients, but not in all patients failing on current therapy (sub-optimal therapy, SOT patients). In the SOT patients, the basecase ICERs exceeded £43,400 and NICE essentially concluded that natalizumab would not be a cost-effective use of NHS resources in these patients unless they were having two or more relapses per year. However, NICE recognised that the evaluation may have underestimated the incremental QALY in two areas. The first was that the relapse disutility was underestimated, and the second was that the time horizon of the evaluation was too short. Here we re-evaluated the ICERs for natalizumab vs. interferon-beta and glatiramer acetate in SOT patients taking into account the points raised by NICE. METHODS: The original model submitted to NICE was a 20-year markov-model parameterised for the UK from a direct health care perspective. Disutilities for relapse were updated using values from a previous UK Health Technology Assessment, and the cost of relapse was changed in line with contemporary studies. The time-horizon for the model was extended from 20 years to 30 years. RESULTS: The ICER from a direct medical costs perspective for natalizumab vs. interferon-beta was £29,900 per QALY. For natalizumab vs. glatiramer acetate the ICER was £29,300 per QALY. CONCLUSION: The European Medicines Evaluation Agency has approved natalizumab for use in highly active RRMS, including SOT patients. Given the willingness-to-pay threshold of £30,000 per QALY commonly associated with NICE guidance, the results here show that natalizumab is a cost-effective treatment for all patients failing on current therapy in the UK. To determine the incremental cost-utility ratio (ICUR) of Sativex®, a novel, cannabis-based therapy, as adjunctive treatment for neuropathic pain in MS adults from a Canadian provincial government payer perspective over a oneyear time horizon. METHODS: Efficacy and safety of Sativex® were extracted from the pivotal phase III trial comparing Sativex®+standard analgesic care (SAC) to SAC alone. Direct medical resources (medication, health professionals, lab and diagnostic) were taken from a burden of illness study. Sativex® utilization for the economic analysis was based on the utilization in the pivotal study (# sprays per day). Costs (2006 CND$) were based on provincial sources. Utilities were based on a mapping exercise whereby pain severity (BS-11) from the pivotal trial was mapped onto Health Utilities Index Mark 3 (HUI) pain attribute level. The primary outcome was the cost per additional quality adjusted life year (QALY). The incremental cost per additional pain-controlled day was a secondary economic outcome. Sensitivity analyses were conducted to investigate the robustness of the results. RESULTS: The total direct cost of treatment over one-year was $12,691 for Sativex® + SAC and $3,340 for SAC. The total QALYs for Sativex® + SAC were 0.3793 and 0.2459 for SAC. The ICUR for Sativex® + SAC compared to SAC was $70,103/QALY. The number of pain controlled days over a one-year time horizon was 196 for Sativex® + SAC and 122 for SAC. Cost drivers were Sativex® utilization (5 daily sprays = $36,512/QALY; 11 sprays = $80,327/QALY). The incremental cost per pain-controlled day was $127. CONCLU-SION: Results indicated that Sativex® + SAC was more expensive than SAC, but provided increased QALYs and pain-control in MS patients with neuropathic pain. 
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cost-utility of interferon beta-1b (IFNB-1b) in the treatment of patients with a clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS).
METHODS:
We developed a Markov model of the epidemiology and treatment of CIS and MS. The model allows users to simulate outcomes over varying time horizons. A hypothetical cohort of 1000 patients with incident CIS was specified, with initial health states defined by Kurtzke Expanded Disability Symptom Scale (EDSS). The cohort was assumed alternatively to be treated with IFNB-1b (250mg eod) following an initial demyelinating event suggestive of MS or not treated until confirmation of MS. Data from a published clinical study (BENEFIT) were used to model EDSS progression over time and transitions from CIS to MS. Relapses were estimated from BENEFIT and published natural history data. Following transition to MS, all patients were assumed to be treated with IFNB-1b until EDSS 6.5. Direct and indirect costs of MS treatment and IFNB-1b were estimated from published literature and pricing schedules. Patient utilities were derived from EQ-5D data from BENEFIT, supplemented by published data defined by EDSS score and relapse occurrence. Mortality was estimated using life tables and EDSS data. Costs (2007 currency) and outcomes were discounted at 5% per annum. Sensitivity analyses were performed on key model parameters. RESULTS: Use of IFNB-1b was associated with slower EDSS progression (hence, longer time to MS diagnosis), and reduced relapse burden. In the base case (Australian perspective; 25-year simulation), incremental cost-utility of IFNB-1b versus no treatment was AUD58,600 (USD$51,400) per quality-adjusted life year (QALY) gained. Findings were sensitive to years simulated, IFNB-1b cost and treatment effect, and underlying rate of disease progression. CONCLUSION: IFNB-1b treatment of patients with CIS apparently offers reasonable value for money relative to many well-accepted health care interventions.
PND16 THE CONCENTRATION AND PERSISTENCE OF HEALTH CARE EXPENDITURES AND PRESCRIPTION DRUG EXPENDITURES IN PATIENTS WITH ALZHEIMER'S DISEASE
Lin PJ, Biddle AK, Maciejewski ML University of North Carolina at Chapel Hill, Chapel Hill, NC, USA OBJECTIVE: Health care expenditures in Medicare are highly concentrated in a small proportion of beneficiaries. The purpose of this study was to quantify the concentration and persistence of overall and prescription drug expenditures in individuals with Alzheimer's disease (AD) and to determine the characteristics associated with future expenditure levels. METHODS: Data were obtained from the 1999-2004 Medicare Current Beneficiary Survey linked with Medicare claims. Elderly, communitydwelling individuals with AD were rank-ordered by overall and drug expenditures. The proportion of expenditures accounted for by the top 10%, top 25% and top 50% of spenders was calculated. A transition probability matrix was used to illustrate the change in expenditure percentiles from one year to the next. Ordered logit models incorporating prior expenditure, Charlson Comorbidity Index, functional status and other background covariates were performed to predict the level of subsequent-year expenditures. RESULTS: The top 10% of spenders accounted for 38%-47% of overall health expenditures and incurred 31%-36% of overall drug expenditures depending on the year. One-quarter of the highest-spending 10% for total health expenditures remained in the top decile in the next year, whereas 21% of them moved to the bottom half in the subsequent year. Half of the highest 10% of drug spenders retained this ranking and 9% moved to the bottom 50% in the next year. Prior expenditures and Charlson comorbidity scores, but not functional status, were strong predictors of the level of future expenditures. CONCLUSION: Overall health care and drug expenditures were highly concentrated and persistent over a twoyear period in this AD population. Prescription drug expenditures exhibited less concentration but more persistence than did overall health expenditures. Results from this study may further our knowledge of how expected high expenditures in AD patients may be reduced with improved care coordination and effective case management.
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